Florinef
(Fludrocortisone)ApprovedSmall molecule
Jazz PharmaceuticalsFludrocortisone is used to treat conditions where the body doesn't produce enough of certain natural hormones, particularly adrenal insufficiency, and helps regulate salt and water balance in the body.[2] Florinef is currently approved and in use across 7 indications[4].[1]
Florinef is one of 221 small molecule programs targeting Borderline personality disorder. It is currently in Approved.
7
Indications
27
Total Trials
3
Active Trials
220
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
112 competitors in Sepsis
#DrugCompanyPhaseTrials
1Florinef
Jazz PharmaceuticalsApproved
Olumiant
Eli LillyPhase 2
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
Actemra
CCelltrion
Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
AZD4144
AstraZenecaPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Septic Shock4 trials
Adjunctive Fludrocortisone in Septic Shock
Not yet recruiting·—·Phase 2·NCT07451886·32 enrolled
Sepsis2 trials
Absorption1 trial
ALD1 trial
The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production
Completed·—·Phase 1·NCT02871648·23 enrolled
15 more indications
Very Premature Infants1 trial
Cognition1 trial
Stress & Social Cognition in BPD (part 2)
Completed·—·N/A·NCT05310253·240 enrolled
Type 1 Diabetes Mellitus1 trial
Prostate Cancer1 trial
Hydrocortisone1 trial
Cognitive Function1 trial
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
Completed·—·N/A·NCT03062150·232 enrolled
Single Dose1 trial
Hypotension1 trial
Gastrointestinal Dysfunction1 trial
Multiple System Atrophy1 trial
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
Completed·—·Phase 1·NCT00103597·50 enrolled
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
FLORINEF
NDA NDA010060
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Florinef drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fludrocortisone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company